<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882177</url>
  </required_header>
  <id_info>
    <org_study_id>StAT-TB</org_study_id>
    <secondary_id>38558</secondary_id>
    <nct_id>NCT03882177</nct_id>
  </id_info>
  <brief_title>StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis</brief_title>
  <official_title>StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of&#xD;
      pravastatin adjunctive therapy when combined with the standard tuberculosis (TB) treatment&#xD;
      regimen in adults with TB.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the safety, tolerability, and pharmacokinetics of pravastatin&#xD;
      adjunctive therapy when combined with the standard TB treatment regimen in adults with&#xD;
      drug-sensitive TB. The pharmacokinetic data for pravastatin will be used to choose a dose to&#xD;
      be studied as adjunctive TB treatment in subsequent trials.&#xD;
&#xD;
      This study is a dose-escalation trial, and participants will be sequentially enrolled into&#xD;
      four study arms. Participants will receive standard anti-TB therapy (Rifafour) and&#xD;
      pravastatin daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin +&#xD;
      Rifafour will be given on Days 2-15.&#xD;
&#xD;
      Total study duration for participants will be 30 days, during which time participants will&#xD;
      attend several study visits. Study visits may include sputum specimen collection, blood and&#xD;
      urine collection, lung function testing, and pharmacokinetic assessments. All study&#xD;
      participants will be referred appropriately to continue standard TB treatment at study&#xD;
      completion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Grade 3 or higher adverse events</measure>
    <time_frame>Measured through Day 30</time_frame>
    <description>Graded using the DAIDS table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who permanently discontinue assigned study regimen for any reason</measure>
    <time_frame>Measured through Day 14</time_frame>
    <description>(Other than new recognition of participant ineligibility based on absence of M. tuberculosis growth in baseline sputum cultures, or growth of M. tuberculosis resistant to rifampin by GeneXpert)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Arm 1: Pravastatin (40 mg) and Rifafour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pravastatin (40 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.&#xD;
Vitamin B6 will be added to each of the regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Pravastatin (80 mg) and Rifafour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pravastatin (80 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.&#xD;
Vitamin B6 will be added to each of the regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Pravastatin (120 mg) and Rifafour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pravastatin (120 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.&#xD;
Vitamin B6 will be added to each of the regimens.&#xD;
(Arm 3 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Pravastatin (160 mg) and Rifafour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pravastatin (160 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.&#xD;
Vitamin B6 will be added to each of the regimens.&#xD;
(Arm 4 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Tablets, administered orally</description>
    <arm_group_label>Arm 1: Pravastatin (40 mg) and Rifafour</arm_group_label>
    <arm_group_label>Arm 2: Pravastatin (80 mg) and Rifafour</arm_group_label>
    <arm_group_label>Arm 3: Pravastatin (120 mg) and Rifafour</arm_group_label>
    <arm_group_label>Arm 4: Pravastatin (160 mg) and Rifafour</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifafour</intervention_name>
    <description>Fixed-dose combination (isoniazid, rifampin, pyrazinamide, and ethambutol) tablets, administered orally</description>
    <arm_group_label>Arm 1: Pravastatin (40 mg) and Rifafour</arm_group_label>
    <arm_group_label>Arm 2: Pravastatin (80 mg) and Rifafour</arm_group_label>
    <arm_group_label>Arm 3: Pravastatin (120 mg) and Rifafour</arm_group_label>
    <arm_group_label>Arm 4: Pravastatin (160 mg) and Rifafour</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin B6</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Arm 1: Pravastatin (40 mg) and Rifafour</arm_group_label>
    <arm_group_label>Arm 2: Pravastatin (80 mg) and Rifafour</arm_group_label>
    <arm_group_label>Arm 3: Pravastatin (120 mg) and Rifafour</arm_group_label>
    <arm_group_label>Arm 4: Pravastatin (160 mg) and Rifafour</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Clinical signs and symptoms of pulmonary tuberculosis&#xD;
&#xD;
          -  Abnormal chest radiograph consistent with pulmonary tuberculosis&#xD;
&#xD;
          -  At least one sputum positive for M. tuberculosis by Xpert MTB/RIF with a cycle&#xD;
             threshold (Ct) less than 28.&#xD;
&#xD;
          -  Documentation of HIV status&#xD;
&#xD;
          -  Weight greater than or equal to 45 kg&#xD;
&#xD;
          -  Karnofsky score of at least 60&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Ability to adhere to study follow-up visits&#xD;
&#xD;
          -  Negative pregnancy test in women of child-bearing age&#xD;
&#xD;
          -  Ability to adhere to contraceptive requirements and willing to use two forms of&#xD;
             contraception: 1) a double barrier method to prevent pregnancy (i.e. use of a condom&#xD;
             with either diaphragm or cervical cap) or 2) use of an intrauterine device in&#xD;
             combination with a barrier contraceptive. The participant must be willing to continue&#xD;
             these contraceptive measures throughout the duration of the study and until one week&#xD;
             after the last dose of study medication or one week after discontinuation from study&#xD;
             medication in case of premature discontinuation.&#xD;
&#xD;
          -  Five days or fewer of anti-tuberculosis treatment within the previous 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of severe adverse reactions to any statin or any other study agent or&#xD;
             contraindications to use of statins.&#xD;
&#xD;
          -  Current use of statins or other lipid-lower agents;&#xD;
&#xD;
          -  Clinical indication for statin therapy based on cardiovascular risk:&#xD;
&#xD;
               -  Familial hypercholesterolemia&#xD;
&#xD;
               -  Previous history of myocardial infarction or stroke&#xD;
&#xD;
          -  For HIV-positive individuals, a CD4+ T-cell count less than 350/mm^3&#xD;
&#xD;
          -  Use of antiretroviral drugs&#xD;
&#xD;
          -  Hemoglobin concentration less than 8 g/dL;&#xD;
&#xD;
          -  Baseline creatinine kinase elevation more than three times the upper limit of normal&#xD;
&#xD;
          -  Abnormal baseline laboratory values&#xD;
&#xD;
               -  Baseline alanine aminotransferase (ALT) concentration more than 2.5 times the&#xD;
                  upper limit of normal (Grade 1)&#xD;
&#xD;
               -  Serum creatinine concentration more than twice the upper limit of normal;&#xD;
&#xD;
               -  Serum total bilirubin level greater than twice the upper limit of normal&#xD;
&#xD;
               -  Platelet count less than 100,000/mm^3&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) less than 1,000/mm^3&#xD;
&#xD;
          -  Pregnant or breastfeeding;&#xD;
&#xD;
          -  Silico-tuberculosis.&#xD;
&#xD;
          -  Currently receiving TB treatment&#xD;
&#xD;
          -  Serologies or PCR positive for viral hepatitis (Hepatitis, B, C)&#xD;
&#xD;
          -  Concomitant disorders or conditions for which isoniazid, rifampin, pyrazinamide, or&#xD;
             ethambutol is contraindicated. These include cirrhosis, acute liver disease of any&#xD;
             cause, acute uncontrolled gouty arthritis and peripheral neuropathy.&#xD;
&#xD;
          -  Any medical or psychological condition which, in the view of the study investigator,&#xD;
             makes study participation inadvisable.&#xD;
&#xD;
          -  Infection with an isolate determined to be resistant to rifampin by GeneXpert.&#xD;
&#xD;
          -  More than five days of anti-tuberculosis treatment within the previous 3 months&#xD;
&#xD;
          -  Planned or current use of cyclosporine, tacrolimus, erythromycin or colchicine&#xD;
&#xD;
          -  Central nervous system (CNS) TB&#xD;
&#xD;
          -  Extra-pulmonary TB only, not in combination with pulmonary TB&#xD;
&#xD;
          -  History of TB&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petros C. Karakousis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard E. Chaisson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil Martinson, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Witwatersrand, South Africa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PHRU Non-Network CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matebogo Letutu</last_name>
      <phone>27-11-9899889</phone>
      <email>letutum@phru.co.za</email>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

